About Achillion
Achillion is a company based in New Haven (United States) founded in 1998 was acquired by Alexion in October 2019. Achillion has raised $41 million across 1 funding round from investors including Alexion, Schroders and GE Capital. Achillion operates in a competitive market with competitors including Eiger BioPharmaceuticals, Aligos Therapeutics, AusperBio, Ascentage Pharma and Bluejay Therapeutics, among others.
- Headquarter New Haven, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Achillion
Unlock access to complete
Funding Insights of Achillion
Achillion has successfully raised a total of $41M through 1 strategic funding round. The most recent funding activity was a Series C round of $41 million completed in January 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Achillion
Achillion has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Alexion, Schroders and GE Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked | |
|
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
|
Locked | Locked | Locked |
Investor details for Achillion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Achillion
Investment portfolio details for Achillion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Achillion
Detailed financials for Achillion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Achillion Comparisons
Peer comparison for Achillion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Achillion
Achillion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Eiger BioPharmaceuticals, Aligos Therapeutics, AusperBio, Ascentage Pharma and Bluejay Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| Locked | Locked | Locked |
Developer of therapies to treat hepatologic diseases and viral infections
|
|
| Locked | Locked | Locked |
Therapies for chronic hepatitis B and infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for infectious diseases treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule antiviral therapeutics for hepatitis C are developed.
|
Detailed competitors of Achillion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Achillion
Complete news archive for Achillion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Achillion
Achillion was founded in 1998 and raised its 1st funding round 4 years after it was founded.
Achillion is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Milind Deshpande is the current CEO of Achillion.
Achillion is a funded company, having raised a total of $41M across 1 funding round to date.
Achillion Pharmaceuticals was founded in 1998 and is based in New Haven, United States, within the biotechnology sector. Focus is placed on developing oral drugs for chronic Hepatitis C, with the lead candidate advancing through phase II trials in partnership with Janssen. An additional Factor D inhibitor is under early-stage evaluation for paroxysmal nocturnal hemoglobinuria, dry age-related macular degeneration, and chronic obstructive pulmonary disease.
Achillion's top competitors include Eiger BioPharmaceuticals, AusperBio and Finch Therapeutics.
Achillion has 9 investors. Key investors include Alexion, Schroders, GE Capital, Atlas Venture, and Bear Stearns Companies.